-7%

est. 2Y upside i

Healthcare

Private sector Healthcare.gov.

Rank

#2458

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

Given the lack of recent valuation data and uncertain growth, the expected upside over 2 years is slightly negative (-6.8%).

Last updated: July 19, 2026

Bull (25%)+61%

IPO window opens, multiple expands to 5x forward revenue, exit value $1.125B, driven by category leadership and enrollment growth.

Base (35%)-4%

Multiple converges to 3x forward revenue, exit value $675M, resulting in slight loss. Steady but no catalyst.

Bear (40%)-52%

Regulatory or competitive pressure compresses multiple to 1.5x, exit value $337.5M, a 51.8% decline. Common stock still recovers preference.

Est. time to liquidity~3.0 years

Preference Stack Risk

low

Funding Intensity

191%

Total preferred stock of $13.4M represents only 1.9% of estimated valuation, minimal overhang.

Dilution Risk

low

Company generates high revenue, likely self-sufficient; no dilutive raise expected.

Secondary Liquidity

none

No active secondary market reported.

Other — 1 role

People & Talent — 1 role

View all 2 open roles at HealthSherpa →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on HealthSherpa's data — designed to show you've done your homework.

  • 1

    “How does the company plan to mitigate the risk of Healthcare.gov enhancing its own direct enrollment capabilities?”

  • 2

    “What is the long-term revenue growth strategy beyond ACA enrollments, such as Medicare or international?”

  • 3

    “Given the lack of recent funding rounds, what is the company's view on employee equity liquidity?”

Community

Valuation Sentiment

Our model estimates -7% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.